Curis Inc (NASDAQ:CRIS)

10.58
Delayed Data
As of 3:59pm ET
 +0.14 / +1.34%
Today’s Change
3.80
Today|||52-Week Range
20.00
-3.82%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$69.0M

Company Description

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

Contact Information

Curis, Inc.
Building C
Lexington Massachusetts 02421
P:(617) 503-6500
Investor Relations:

Employees

Shareholders

Mutual fund holders4.18%
Other institutional24.82%
Individual stakeholders--

Top Executives

James E. DentzerPresident, Chief Executive Officer & Director
Diantha DuvallCFO, Treasurer & Chief Accounting Officer
Mark W. NoelVP-Technology Management & Intellectual Property
Robert E. MartellHead-Research & Development
Reinhard von RoemelingSenior Vice President-Clinical Development